// App-Quantinova.ai

930 : Safety and Efficacy of Vesatolimod (GS‐9620) in Patients with Chronic Hepatitis B (CHB) Who Are Not Currently on Antiviral Treatment

Researchers

Presenter

  • Kosh Aaarwal

Principal Investigators

  • Sang Hoon Ahn

  • Magdy Elkhashab

  • Kyungpil Kim

  • Audrey H. Lau

  • Anuj Gaggar

  • Mani Subramanian

  • John G. McHutchison

  • Pietro Andreone

  • Hyung J. Kim

  • Wan- Long Chuang

  • Mindie H. Nguyen

Medical Centers

  • Institute of Liver Studies, Kings CollegeHospital NHS Trust, London , United Kingdom

  • Toronto Liver Centre, Toronto, Ontario, Canada

  • Yonsei University Health System, Seoul, Korea

  • Gilead Sciences, Inc., Foster City, CA

  • Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca per lo Studio delle Epatiti, University of Bologna, Bologna, Italy

  • Ophthalmology, Hanyang University, Seoul, Korea (the Republic of)

  • Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

  • Stanford Univ, Palo Alto, CA

Locations

  • United Kingdom

  • Canada

  • Republic of South Korea

  • United States

  • Italy

  • Taiwan

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis B

Biomarkers

  • Alanine transaminase

  • Hepatitis B surface antigen

  • Hepatitis B e antigen

  • Serum hepatitis B virus DNA

Drug/Treatment

  • Vesatolimod

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved